Overview
- The company is pivoting from scarcity-driven pricing to access economics, prioritizing prescription volume over net price as Zepbound scales and oral orforglipron advances in late-stage development.
- Recent quarterly results included revenue and EPS beats, operating margin expansion to 48% year over year, and cash from operations of about $8.8 billion.
- Flagship incretins Mounjaro and Zepbound posted triple-digit year-over-year sales growth, reinforcing leadership in the weight-management market.
- Late-stage assets including orforglipron and multi-agonist retatrutide are cited by analysts as extending obesity treatment leadership and opening broader oral options.
- Valuation remains elevated with a P/E above 45 even as some point to a favorable PEG ratio, and the outlook faces risk from multiple compression despite strong cash flow and diversification moves involving Nimbus and Superluminal.